In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

A weekend leverage flush pushed BTC below $88,000 before a sharp rebound. Bitcoin is trading at a pivotal level that analysts say could determine whether the market holds its broader uptrend or slips ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Is the S&P 500 index’s recent rally real, or is it just a bear-market bounce? That’s always a question investors have when the market is rising after a significant selloff. Given all the uncertainty ...